.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FF12_Serplulimab.Serplulimab

Information

Serplulimab is a fully human IgG4 monoclonal antibody inhibiting PD-1 (programmed cell death protein 1), used as an immune checkpoint inhibitor, primarily investigated and approved in China for the treatment of certain advanced or metastatic cancers, including microsatellite instability-high (MSI-H) solid tumors. As of 2024, it is not globally approved but is undergoing clinical studies in various indications.

Pharmacokinetics

Population pharmacokinetic estimates in adult cancer patients based on phase I/II clinical study data; values reflect mean estimates post intravenous infusion.

References

1. Ho, CL, et al., & Lin, HY (2024). Safety, Tolerability, and Preliminary Efficacy of Serplulimab, a Novel Anti-PD-1 Antibody, in Patients with Metastatic or Recurrent Solid Tumors: A Phase I Study. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38(2) 287–299. DOI:10.1007/s40259-023-00639-w PUBMED:https://pubmed.ncbi.nlm.nih.gov/38194016

Revisions

• 06/2025 initial generated model